Analyst Report: JNJ

1. EXECUTIVE SUMMARY

Johnson & Johnson fell 5.73% to $248.61 on Tuesday October 13, 2026, the day it reported third-quarter results, on volume of 16,620,900 shares, 2.54 times the 50-session average. Adjusted EPS of $2.59 and revenue of $25.4bn beat consensus (Reuters), yet investors focused on a second straight MedTech sales miss, with sales of $8.6bn against an LSEG estimate of $8.71bn, and on a Middle East drag cited by management. Pharma peers fell between 0.11% and 2.39% over the same period, so the move was largely specific to J&J, although other device makers also fell in sympathy. The shares now sit below the 50-day average and above the 200-day average, and the next test is whether MedTech improves in the fourth quarter and how the DePuy Synthes separation develops.

2. THE CATALYST

J&J reported before the open on October 13. Reuters (via Devdiscourse) said shares were already down more than 2% before the bell, and the decline built through the session to the close in the facts.

Outside the US, MedTech sales were roughly flat, according to Reuters. Management attributed the weakness to the Middle East conflict, European austerity and Chinese pricing. The MedTech chief said performance fell below internal standards and previously communicated expectations. Abiomed sales were weak after a UK study questioned Impella use in certain high-risk procedures (AOL/Reuters).

Full-year guidance moved only slightly: the reported sales midpoint to about $101.2bn from $101.1bn, and the adjusted EPS midpoint to $11.10 from $11.04 (BNN Bloomberg). GAAP EPS was $0.09 after a special charge of about $7bn tied to talc litigation and M&A, and adjusted EPS fell 7.5% year on year (Motley Fool transcript).

The CFO also said J&J leans toward spinning off DePuy Synthes rather than selling it (WSJ via Seeking Alpha, Reuters). The sources do not tie the drop mainly to this news.

3. COMPANY PROFILE

Johnson & Johnson operates two segments, Innovative Medicine and MedTech. Innovative Medicine covers oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. It competes with large pharmaceutical companies such as Lilly, Merck, Pfizer and Bristol Myers Squibb. MedTech competes with device makers including Medtronic, Abbott, Stryker, Boston Scientific and Zimmer Biomet. The market capitalisation is $599.12bn.

Pharma sales rose 7.7% to $16.76bn in the quarter (Reuters). Innovative Medicine operating margin fell to 35.4% from 44.3%, mainly from acquired in-process R&D, including about $1bn tied to the Firefly Bio acquisition. MedTech operating margin rose to 22.9%, helped by tariff recoveries (Motley Fool transcript). Management held full-year free cash flow guidance at $21bn after $6bn in the quarter. Net debt is about $28bn, made up of $45bn gross debt and $17bn in cash and securities.

4. DEEP DIVE ANALYSIS

Do fundamentals justify the move? The headline beat and the small guidance increase do not match a 5.73% fall by themselves. The size of the reaction fits a market that had priced in a MedTech recovery, since this was the second consecutive miss and management acknowledged it fell short of its own expectations. The facts show the shares had risen 21.83% year to date and traded at a forward P/E of 20.8, so the stock carried expectations into the print. That reading is inference.

Comparable episodes. Benzinga used the April 1, 2025 session as the benchmark, when the stock lost about 7.6% after a judge rejected its talc settlement. A prior MedTech miss on April 16, 2024 produced a decline of about 1.3% (Reuters via Yahoo Finance), and it came before the DePuy separation plan, which J&J announced on October 14, 2025 (Health Exec). The current reaction is far larger than the 2024 one.

Peers and sector. Pharma peers moved little: LLY -1.36%, MRK -2.39%, PFE -0.11%, BMY -1.58%. Reuters reported Boston Scientific down nearly 3% and Intuitive Surgical about 2%, and Rallies listed Abbott, Boston Scientific, Medtronic, Intuitive, Stryker and Zimmer Biomet down 1% to 4%. JPMorgan's Robbie Marcus said J&J's results are hard to generalise to medtech because of China supply disruption, the pending orthopedics spin and heavier Middle East exposure. Management also cited disrupted ordering and delayed tender decisions across a group of countries (Motley Fool transcript).

Bull case. Pharma grew 7.7%, Tremfya beat by a wide margin and Stelara held above expectations. The CFO said MedTech fundamentals remain strong and that J&J is not cash-constrained, so it can wait to separate the unit next year (CNBC/AOL). MedTech margin improved, free cash flow guidance held, and guidance edged up. Bloomberg reported in September that Apollo was in talks to buy the orthopedics unit at close to $20bn (Reuters via AOL), which would crystallise value if a deal emerged.

Bear case. MedTech has missed twice in a row, the Middle East and Europe pressures have no stated end date, and Abiomed faces a clinical-evidence question. Darzalex missed, Innovative Medicine margin fell sharply, and adjusted EPS declined 7.5% year on year. Trailing P/E is 28.8.

5. TECHNICAL SNAPSHOT

The close of $248.61 is the lowest in the ten-session table, so there is no nearby support among those closes; the 200-day average at $241.55 is the next reference below. The price is below the 50-day average of $264.98 and 11.5% below the 52-week high of $281.07 set on September 2, while remaining far above the 52-week low of $180.59. Resistance sits at $252.93, the October 5 close. Volume of 2.54 times the 50-session average shows heavy participation in the sell-off. The earlier sessions on October 1, 2 and 5 also carried elevated volume as the price slid, before the shares recovered to $263.73.

6. RISK FACTORS

• Further MedTech misses, with the Middle East conflict, European austerity and Chinese pricing named as the pressures.
• Abiomed demand after the UK study on Impella.
• Talc litigation, which produced the special charge in the quarter.
• DePuy Synthes execution: separation is targeted for mid-2027 (Reuters via AOL). Bloomberg reported that an Apollo deal could come within several weeks, though talks could fail or another bidder could emerge. That report dates from roughly September and is approximate.
• Analyst targets in the brief predate the print, and no post-earnings rating or target changes were found. Pre-print actions included Stifel Hold at $260, Bank of America Hold at $282, UBS Buy at $320 and Citigroup Buy at $303, and target cuts are possible.
• The facts list October 13 as the next earnings date, which is the report just released. No later date is confirmed.

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks): Analyst revisions after the print and any news on the Apollo talks or the DePuy structure drive the direction. The 200-day average at $241.55 is the level to watch on the downside, and $252.93 is the first resistance on a rebound.

Medium term (1-3 months): Management said it is focused on improving MedTech performance in the fourth quarter. Evidence of stabilisation in ordering and tenders would support a recovery toward the 50-day average, while another miss would extend the derating.

Long term: The thesis rests on Innovative Medicine growth, $21bn of free cash flow and the DePuy separation. One quarter of MedTech weakness has not changed that, although a second consecutive miss raises the bar for the segment's credibility. This is analysis only and not personal financial advice.